A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease.
To determine whether seven days oral D-ribose would improve exercise tolerance in a group of 5 patients with McArdle's disease, we performed a double blind placebo controlled crossover trial. Subjects performed weekly treadmill exercise tests with expired gas analysis until their times were reproducible. They then received 60 g D-ribose daily or placebo for seven days. Exercise testing was repeated on completion of this period. A seven day washout period then followed. Subjects then performed a new baseline exercise test prior to starting the other solution. Again after seven days the exercise test was repeated. There was no significant difference between pre-treatment exercise tests for peak oxygen consumption or level of leg fatigue. Patients did not like taking the ribose and D-Ribose does not appear to be of benefit to patients with McArdle's disease.
Steele
I C
IC
Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Patterson
V H
VH
Nicholls
D P
DP
D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology; D005080:Exercise Test; D005260:Female; D006012:Glycogen Storage Disease Type V / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018763:Muscle Fatigue / Q000502:physiology; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D012266:Ribose / Q000627:therapeutic use*
D012266:Ribose